1300 564 799
Loading Events

« All Events

Spectrumceuticals 2018 Practitioner Seminar

November 17 - November 18

Spectrumceuticals 2018 Practitioner Seminar

Systemic Approaches to Chronically Ill Patients Using Integrative Medicine
17-18 November, 2018

Over the two days of our 2018 Practitioner Seminar content will cover the diagnosis and management of chronic fatigue syndrome, vector borne illnesses and chronic inflammatory response syndrome (CIRS) as well as interactive workshops and small group discussions.

The aim is to develop the skills of the integrative medical practitioner in the clinical management of these complex illnesses.

Key Topics

Chronic fatigue syndrome, vector borne illnesses

It is estimated that as many as 250,000 Australians are affected by ME/CFS. Many go undiagnosed for years or are deemed too difficult to manage, numerous of them suffering long-term morbidity.

Dr Schloeffel has developed a system of diagnosing and treating these patients with consistent positive outcomes. These innovative diagnostic concepts allow physicians and health care practitioners to negotiate the complex symptoms these patients experience.

Over 4,000 patients have been seen at Dr Schloeffel’s practice over a 20-year period. Time has revealed a substantial number suffering Vector Borne Illness inclusive of Boreliosis and co-infections.

Australia is in a unique position regarding Tick Borne Illness – the science is in its infancy showing only preliminary evidence of Borreliosis in its ticks. The current evidence suggests a relapsing fever type of Borreliosis. Co-infections, particularly Rickettsia, Bartonella, Mycoplasma, Ehrlichia, Anaplasmosis, Q-fever and viruses are well documented.

Babesia has been found in some patients without any history of foreign travel lending itself to the understanding that we have vectors carrying this disease. Patients presenting with CFS or VBI are particularly challenging.

The aim of this forum is to guide you, the practitioner, through a comprehensive understanding from diagnosis to recovery for these often ‘Heartsink’ patients.

Chronic inflammatory response syndrome (CIRS)

It was in the 1990s when Dr Shoemaker of Maryland, USA, linked an illness to a toxin produced by a fish-killing dinoflagellate known as Pfiesteria. Since then, Dr Shoemaker and others have linked the same kind of illness to toxins from mould and termed this illness CHRONIC INFLAMMATORY RESPONSE SYNDROME (CIRS).

CIRS occurs when genetically susceptible people are exposed to certain biotoxins – species of Stachybotris, Aspergillus, Penicillium, Chaetomium and Wallemia and possible links to associated tick-borne microbes.

In the late 2000s a nasal spray of vasoactive intestinal polypeptide (VIP) seemed to be a major breakthrough in lowering cytokine levels, particularly C4a, MMP-9 and TGF-beta-1.

The research has continued to the stage where we have around 20 peer reviewed papers, on what has now being called chronic inflammatory response syndrome (CIRS). And although the research is ongoing, the question needs to be asked with all chronically ill patients with multisystem disorders; ‘is your patient suffering with a chronic version of sepsis syndrome?’

Venue Details

Manly Sebel, 8/13 S Steyne, Manly, New South Wales 2095 Australia

Register / Cost

To view pricing and to register online for this conference click here.

Details

Start:
November 17
End:
November 18
Event Category:
Website:
https://spectrumceuticals.com/events/2018-11-17/

Organiser

Spectrumceuticals